Followers | 14 |
Posts | 1041 |
Boards Moderated | 0 |
Alias Born | 10/20/2017 |
Wednesday, July 07, 2021 4:21:14 PM
If you look at the 6 month trend, the 1 year trend and the 5 year trend we are "up trending." Stocks don't just shoot up, although Sorrento deserves to move parabolically to the upside, but the revenues don't justify the market cap to be higher than this price. With the EUA in Mexico for Covi-stix and future approvals, which we will definitely have, the stock will explode parabolically and exponentially. If you want to get rid of your shares you're not thinking rationally, you're thinking on emotion. Emotional traders lose out on great investments by giving up. If you have to, sell part of it if you need to justify your anger and think other stocks will make you happier, but hold on to a good portion of Sorrento Therapeutics because it will be successful in the coming months and years. Holding 17K shares.
If you are tired of hearing the word patience than you are not patient.
Next stop HUMBL Street. Transfers to the S the R the N and the E train.Beware of the closing doors please.
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM